Compare Novo Nordisk A/S (NVO) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Riot Platforms Inc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Riot Platforms Inc trades at $16.89 (market cap $6.32B). The key difference: Novo Nordisk A/S is far larger — about 26.2× Riot Platforms Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Riot Platforms Inc for 16 Days on average.
| NVO | RIOT | |
|---|---|---|
Market Cap | $165.31B | $6.32B |
Volume | 11,432,838 | 30,571,756 |
Sector | Health | Financials |
52-Week High | $63.98 | $28.67 |
52-Week Low | $35.29 | $11.83 |
Typical Hold Time | 116 Days | 16 Days |
Enterprise Value | $179.56B | $6.73B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
RIOT Platforms trades at $16.885, down 8.93% on the day, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported significant losses with a net income margin of -196.28% in 2026, though revenue grew to $675 million. Recent strategic shifts toward AI data center leasing, including a $9.1 billion contract, highlight transformation efforts amid challenging profitability.
While analyst consensus remains strongly bullish with a $31.64 price target, substantial execution risks and persistent negative earnings pose challenges. The stock's outlook hinges on successful monetization of AI infrastructure contracts and improved operational efficiency to stem cash flow deficits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
